alexa

GET THE APP

A Comparative Study of the Efficacy and Safety of Olanzapine and Aprepitant Regimens in Highly Emetogenic Chemotherapy | OMICS International| Abstract
ISSN: 2165-7386

Journal of Palliative Care & Medicine
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • J Palliat Care Med 363,
  • DOI: 10.4172/2165-7386.1000363

A Comparative Study of the Efficacy and Safety of Olanzapine and Aprepitant Regimens in Highly Emetogenic Chemotherapy

M Prasad1*, Ananya Chakraborty1 and Shashidhar VK2
1Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, White Field, Bangalore, Karnataka, India
2Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Centre, White Field, Bangalore, Karnataka, India
*Corresponding Author : M Prasad, Department of Pharmacology, Vydehi Institute of Medical Sciences and Research Centre, White Field, Bangalore, Karnataka, India, Tel: +91 9591408218, Email: [email protected]

Received Date: Jun 03, 2019 / Accepted Date: Sep 06, 2019 / Published Date: Sep 14, 2019

Abstract

Aim: To compare the efficacy and safety of Olanzapine and aprepitant regimens in highly emetogenic Chemotherapy (HEC).
Materials and methods: A randomized, prospective study was conducted in tertiary care hospital, Bangalore. 84 participants were randomized into two groups. Group A (OPD) received on Day 1 (30 mins prior to chemotherapy):Tab Olanzapine 10 mg p/o, Inj Palonosetron 0.25 mg i.v. and Inj Dexamethasone 20 mg i.v. and on Day 2-Day 4: Tab Olanzapine 10 mg p/o once daily. Group B (APD) received on Day 1 (30 mins prior to chemotherapy): Tab Aprepitant 125 mg p/o, Inj Palonosetron 0.25 mg iv and Inj. Dexamethasone 12 mg i.v. on Day 2-Day 3: Tab Aprepitant 80 mg p/o once daily and Tab Dexamethasone 8 mg p/o once daily, on Day 4: Tab Dexamethasone 8 mg p/o once daily.
Results: In OPD group CR was seen in 88%, 86% and 78% in acute (0-24 hrs), delayed (24-120 hrs) and overall period (0-120 hrs) respectively. In APD group CR was seen in 86%, 83% and 70% in acute, delayed and overall period respectively. Adverse drug reactions (ADR's) were seen in total of 12 participants, 6 in each group, there were no significant grade 3 or 4 toxicities. In OPD group Average FLIE scores on day 1 and day 6 were 30.34 and 32.47 respectively while in APD group it was 32.47 and 39.18 respectively.
Conclusion: Both APD and OPD regimens were comparable in controlling CINV in acute and delayed period. OPD regimen was better in overall period and had less impact on QOL compared to APD regimen.

Keywords: 5-HT3RA; NK1-receptor antagonist; Highly emetogenic chemotherapy

Citation: Prasad M, Chakraborty A, Shashidhar VK (2019) A Comparative Study of the Efficacy and Safety of Olanzapine and Aprepitant Regimens in Highly Emetogenic Chemotherapy. J Palliat Care Med 6:363. Doi: 10.4172/2165-7386.1000363

Copyright: © 2019 Prasad M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top